About Proteomics International
Proteomics International is a company based in Perth (Australia) founded in 2001 by Richard Lipscombe.. Proteomics International offers products and services including PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx. Proteomics International operates in a competitive market with competitors including Metabolon, Maze Therapeutics, Alector, Seer and Tango Therapeutics, among others.
- Headquarter Perth, Australia
- Founders Richard Lipscombe
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Proteomics International Laboratories Ltd
-
Annual Revenue
$634.59 K (USD)7.65as on Jun 30, 2025
-
Net Profit
$-5.36 M (USD)-27.27as on Jun 30, 2025
-
EBITDA
$-6.56 M (USD)-21.4as on Jun 30, 2025
-
Latest Funding Round
$4.28 M (USD), Post-IPO
Jan 23, 2024
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Proteomics International
Proteomics International is a publicly listed company on the ASX with ticker symbol PIQ in Australia, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Proteomics International
Proteomics International offers a comprehensive portfolio of products and services, including PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Predictive test for diabetic kidney disease detection
Blood test for endometriosis diagnosis accuracy
Esophageal cancer diagnostic with high accuracy
Tool for oxidative stress analysis in health research
Unlock access to complete
Unlock access to complete
Funding Insights of Proteomics International
- Total Funding Total Funding
- Total Rounds 8
- Last Round Post-IPO — $4.3M
-
First Round
First Round
(22 Jul 2012)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2024 | Amount | Post-IPO - Proteomics International | Valuation |
investors |
|
| Aug, 2022 | Amount | Post-IPO - Proteomics International | Valuation |
investors |
|
| May, 2022 | Amount | Grant - Proteomics International | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Proteomics International
Proteomics International has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include MTPConnect. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Australia's life sciences innovation is accelerated by MTPConnect.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Proteomics International
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Proteomics International
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Proteomics International Comparisons
Competitors of Proteomics International
Proteomics International operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Maze Therapeutics, Alector, Seer and Tango Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| domain | founded_year | HQ Location |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| domain | founded_year | HQ Location |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
|
| domain | founded_year | HQ Location |
Proteomics platform developed for early cancer and neurological disease detection.
|
|
| domain | founded_year | HQ Location |
Novel cancer drugs are developed using synthetic lethality screening.
|
|
| domain | founded_year | HQ Location |
NeoPhore is focused on cancer neoantigen evolution therapies.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Proteomics International
Frequently Asked Questions about Proteomics International
When was Proteomics International founded?
Proteomics International was founded in 2001 and raised its 1st funding round 11 years after it was founded.
Where is Proteomics International located?
Proteomics International is headquartered in Perth, Australia. It is registered at Perth, Western Australia, Australia.
What is the annual revenue of Proteomics International?
Annual revenue of Proteomics International is $634.59K as on Jun 30, 2025.
What does Proteomics International do?
Medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company develop and commercializes diagnostic tests known as PromarkerD, for the detection of diabetic kidney disease. Company specialises in the area of proteomics, the industrial scale study of the structure and function of proteins. It also, offers analytical services for research purposes. The technology can be used to identify fingerprints from any biological source, from wheat seeds to human serum.
Who are the top competitors of Proteomics International?
Proteomics International's top competitors include Alector, Lexicon Pharmaceuticals and Maze Therapeutics.
What products or services does Proteomics International offer?
Proteomics International offers PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
Is Proteomics International publicly traded?
Yes, Proteomics International is publicly traded on ASX under the ticker symbol PIQ.
Who are Proteomics International's investors?
Proteomics International has 1 investor. Key investors include MTPConnect.
What is Proteomics International's ticker symbol?
The ticker symbol of Proteomics International is PIQ on ASX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.